CTXR · Citius Pharmaceuticals Inc
United States · RS rating 32 · As of 2026-11-03
| Price | 0.57 USD |
|---|---|
| 1-day change | +2.0% |
| RS rating (overall / 1M / 3M / 12M) | 32 / 82 / 24 / 15 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 14 / 17 / 35 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -150.0% |
| Sales growth Q/Q | -57.7% |
| Distance from 52-week high | +62.3% |
| Market cap (USD) | $20.9M |